Call Options on VKTX on 7/29/2024

Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.

The company was incorporated in 2012 and is headquartered in San Diego, California.

We will be trading August 16th Call Options.

Last Trade: $62.24

Trading Range: $8.28 - $99.41

Trade Buy 1 August $70.00 Call at $2.30 For a net debit of $2.30 Profit/Loss Analysis Breakeven at $72.30 Maximum profit is unbounded Maximum loss is ($230.00) at strike of $70.00 Closing Summary Sold 1 August $70.00 Call at $0.00

Position closed on 8/20/2024 at price of $0.00 with a -100.00% loss in 22 days.

Back to Portfolio